Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 13, 2026
TickeronGET DAILY SIGNALS
BKYI vs TCRT: Two Sub-$1 Nasdaq Micro-Caps With Very Different Paths

BKYI vs TCRT: Two Sub-$1 Nasdaq Micro-Caps With Very Different Paths

Key Takeaways

  • BKYI (BIO-key International) is a provider of biometric identity and access management (IAM) solutions, while TCRT (Alaunos Therapeutics) is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancer.
  • Both are Nasdaq-listed micro-cap stocks trading below $1, exposing each to minimum bid price listing-compliance risk.
  • BIO-key has been building momentum in hardware sales and defense/financial contracts; Alaunos has recently reestablished equity compliance but remains thinly traded and dependent on external financing.
  • BKYI has a near-term revenue path toward break-even, while TCRT's value hinges on clinical progress and capital-raising catalysts.
  • The two names carry fundamentally different risk profiles: execution and technology risk for BKYI versus clinical trial and funding risk for TCRT.

Why These Two Stocks Stand Out

Investors comparing BKYI and TCRT are weighing two very different business models operating in the same sub-$1 micro-cap segment of the Nasdaq Capital Market. One is a commercial-stage biometric security vendor with recurring software and hardware revenue; the other is a pre-revenue clinical-stage biotechnology firm focused on cell therapy for solid tumors. This stock comparison examines relative performance, market positioning, and risk factors, making it relevant to traders and investors who follow small-cap momentum, turnaround situations, and high-risk growth narratives. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their industries.

BKYI Overview and Recent Performance

BIO-key International provides biometric fingerprint identification and identity and access management (IAM) platforms, including its PortalGuard identity platform and WEB-key biometric infrastructure software, serving education, financial, government, and defense customers. In recent market activity, BKYI has experienced pronounced volatility, including sharp single-day moves tied to contract announcements, while trading near the lower end of its 52-week range.

In recent quarters, the company reported a revenue decline driven by tough year-over-year comparisons from large one-time orders, though hardware revenue grew by more than 100% in fiscal 2025 and gross margins have remained strong at roughly 77%. Management has cited a significantly improved cash position and higher book value, and has pointed to new defense-sector deployments, a renewed financial-sector license, and a U.S. public-sector distribution partnership as growth drivers. The stock's sentiment has been shaped by these contract wins and product launches alongside ongoing profitability challenges and Nasdaq minimum bid price compliance risk.

TCRT Overview and Recent Performance

Alaunos Therapeutics is a clinical-stage biopharmaceutical company developing adoptive TCR-T (T-cell receptor engineered T-cell) therapies designed to treat multiple solid tumor types. As a pre-revenue developer, TCRT generates no meaningful product sales, and its shares have been thinly traded and highly volatile in recent months, trading below $1.

Recent market activity has been influenced by regulatory and financing developments. The company previously received a Nasdaq delisting notice after stockholders' equity fell below the required threshold, and it has since worked to reestablish compliance, reporting improved equity in its most recent quarterly filing. Alaunos has also entered into equity financing arrangements, such as a purchase agreement, to fund operations, which filings note could create substantial dilution for existing holders. Investor sentiment remains tied to the company's clinical progress and its ability to secure continued funding, rather than to near-term revenue fundamentals.

Head-to-Head Comparison

The clearest contrast between these two companies is their business model. BIO-key operates a commercial, revenue-generating software and hardware business with recurring service fees, while Alaunos is a clinical-stage biotech with no product revenue. This difference shapes their relative performance drivers: BKYI responds to contract wins, renewals, and product launches, whereas TCRT responds to clinical milestones, regulatory updates, and financing events.

On risk, both face Nasdaq listing-compliance challenges, but the nature of the risk differs. BKYI carries execution, technology, and profitability risk, yet it has a stated goal of reaching break-even and a clearer near-term revenue trajectory. TCRT carries the higher binary risk typical of early-stage drug development, including dilution from equity financings and dependence on capital markets. Sector exposure is also distinct: BKYI sits within the cybersecurity and identity management space, while TCRT sits within oncology and cell therapy.

Market sentiment has been volatile for both, but BKYI benefits from recurring revenue visibility and tangible catalysts, while TCRT's sentiment is more speculative and financing-driven. From what I see, this distinction matters when assessing near-term moves.

Tickeron AI Verdict

Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor BKYI over TCRT in the current environment. BIO-key presents a more diversified catalyst base—recurring software revenue, growing hardware sales, and expanding defense and financial contracts—alongside a stronger balance sheet position. Alaunos, by contrast, depends on higher-variance clinical and financing events and trades with limited liquidity. This assessment is probabilistic rather than definitive, reflecting the relative stability and catalyst density of each name. I’m watching this closely as new contract or trial updates emerge.

Using Tickeron’s AI Tools for Deeper Analysis

In my own process, I often review Tickeron’s AI Trading Bots to see how quantitative strategies are positioned around names like these. The curated Trending AI Robots section highlights bots suited to current conditions, offering insight into which automated approaches may be finding an edge with volatile micro-caps. This has helped me cross-check my own views on relative risk and catalyst timing without replacing independent research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TCRT, BKYI

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


TCRT in +7.50% Uptrend, growing for three consecutive days on November 18, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TCRT advanced for three days, in 182 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 72 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

TCRT moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for TCRT moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRT as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TCRT turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 10-day moving average for TCRT crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TCRT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.780) is normal, around the industry mean (3.596). P/E Ratio (-0.994) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer treatment company

Industry Biotechnology

Industry
Biotechnology
Address
501 East Las Olas Boulevard
Phone
+1 346 355-4099
Employees
1
Web
https://www.alaunos.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.